
Opinion|Videos|May 10, 2024
The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer
Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Key Health Care Changes During Trump’s First Year Back in Office
2
J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort
3
Maternal Morbidity Increased in States Enacting TRAP Laws
4
Zanidatamab Shows Breakthrough Survival Gains in Metastatic Gastroesophageal Cancer: Elena Elimova, MD
5






























































